3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
50
Neoplasms
22
Pancreatic Neoplasms
21
Neoplasm Metastasis
12
Lung Neoplasms
12
Brain Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Head and Neck Neoplasms
7
Breast Neoplasms
7
Gliosarcoma
6
Glioblastoma
6
Salivary Gland Neoplasms
5
Rectal Neoplasms
5
Glioma
5
Colorectal Neoplasms
5
Colonic Neoplasms
5
Astrocytoma
5
Unspecified Adult Solid Tumor, Protocol Specific
4
Solid Tumors
4
Esophageal Neoplasms
4
Tongue Neoplasms
3
Prostatic Neoplasms
3
Oligodendroglioma
3
Lymphoma
3
Gallbladder Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Hepatocellular
3
Bile Duct Neoplasms
3
Advanced Cancers
3
Advanced Cancer
3
Interventions
Cyclophosphamide
17
Dexamethasone
15
Bortezomib
14
fludarabine phosphate
12
Melphalan
12
Lenalidomide
10
fludarabine
9
Filgrastim
8
pomalidomide
7
Tacrolimus
7
Peripheral Blood Stem Cell Transplantation
7
Rituximab
6
Radiotherapy
6
Etoposide
6
Whole-Body Irradiation
5
Cord Blood Stem Cell Transplantation
5
Calcium Dobesilate
5
Busulfan
5
Antilymphocyte Serum
5
sargramostim
4
Sirolimus
4
Panobinostat
4
Mycophenolic Acid
4
Methylprednisolone
4
Cyclosporine
4
carfilzomib
3
Vorinostat
3
Stem Cell Transplantation
3
Prednisone
3
Methotrexate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Neoplasms, Plasma Cell
×
Erlotinib Hydrochloride
×
Clear all
NCT00725634
2014-01-27
P05538
AVEO Pharmaceuticals, Inc.
Phase 1
Completed
41 enrolled